---
title: "Chlorprothixene - Schizophrenia"
sidebar: mydoc_sidebar
permalink: db01239-mesh-d012559-1.html
toc: false 
---


Path ID: `DB01239_MESH_D012559_1`
{% include image.html url="images/db01239-mesh-d012559-1.png" file="db01239-mesh-d012559-1.png" alt="db01239-mesh-d012559-1" %}

## Concepts

|------------|------|---------|
| Identifier | Name | Type    |
|------------|------|---------|
| <a href="https://identifiers.org/MESH:D002749">MESH:D002749 </a> | chlorprothixene | Drug |
| <a href="https://identifiers.org/InterPro:IPR000995">InterPro:IPR000995 </a> | Muscarinic acetylcholine receptor family | GeneFamily |
| <a href="https://identifiers.org/InterPro:IPR002231">InterPro:IPR002231 </a> | 5-hydroxytryptamine receptor family | GeneFamily |
| <a href="https://identifiers.org/InterPro:IPR000929">InterPro:IPR000929 </a> | Dopamine receptor family | GeneFamily |
| <a href="https://identifiers.org/GO:0014046">GO:0014046 </a> | dopamine secretion | BiologicalProcess |
| <a href="https://identifiers.org/GO:0007274">GO:0007274 </a> | neuromuscular synaptic transmission | BiologicalProcess |
| <a href="https://identifiers.org/GO:0007213">GO:0007213 </a> | G protein-coupled acetylcholine receptor signaling pathway | BiologicalProcess |
| <a href="https://identifiers.org/HP:0011442">HP:0011442 </a> | Abnormal central motor function | PhenotypicFeature |
| <a href="https://identifiers.org/MESH:D012559">MESH:D012559 </a> | Schizophrenia | Disease |
|------------|------|---------|

## Relationships


NOTE: predicates are annotated in <a href="https://github.com/biolink/biolink-model/releases/tag/v1.3.0">Biolink Model (v1.3.0)</a>

|---------|-----------|---------|
| Subject | Predicate | Object  |
|---------|-----------|---------|
| Chlorprothixene | DECREASES ACTIVITY OF | Muscarinic Acetylcholine Receptor Family |
| Chlorprothixene | DECREASES ACTIVITY OF | Dopamine Receptor Family |
| Chlorprothixene | DECREASES ACTIVITY OF | 5-Hydroxytryptamine Receptor Family |
| Muscarinic Acetylcholine Receptor Family | POSITIVELY REGULATES | Neuromuscular Synaptic Transmission |
| Neuromuscular Synaptic Transmission | POSITIVELY CORRELATED WITH | Abnormal Central Motor Function |
| Abnormal Central Motor Function | MANIFESTATION OF | Schizophrenia |
| 5-Hydroxytryptamine Receptor Family | POSITIVELY REGULATES | Dopamine Secretion |
| Muscarinic Acetylcholine Receptor Family | POSITIVELY REGULATES | G Protein-Coupled Acetylcholine Receptor Signaling Pathway |
| G Protein-Coupled Acetylcholine Receptor Signaling Pathway | POSITIVELY CORRELATED WITH | Dopamine Secretion |
| Dopamine Receptor Family | POSITIVELY REGULATES | Dopamine Secretion |
| Dopamine Secretion | POSITIVELY CORRELATED WITH | Schizophrenia |
|---------|-----------|---------|

Comment: Muscarinic receptor antagonists (also known as anticholinergics) seem to be used in patients with Schizophrenia to alleviate motor side effects caused by first-generation antipsychotics. However these antagonists do seem to lead to cognitive dysfunction in healthy controls. So whether these muscarinic receptors should be positively or negatively regulated in schizophrenia is a matter of debate (see [https://www.nature.com/articles/4001924](https://www.nature.com/articles/4001924) [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3726271/).](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3726271/).) In addition, some suggest that that schizophrenia involves an overactivation of cholinergic neurons, which could provide cholinergic input to dopaminergic neurons. The dopamine neurons are located in the mesolimbic dopaminergic system (BTO:0005591), which is a component pathway of the medial forebrain bundle (UBERON:0001910). See [https://en.wikipedia.org/wiki/Medial_forebrain_bundle#Anatomy](https://en.wikipedia.org/wiki/Medial_forebrain_bundle#Anatomy) for more details.

Reference: 
  - [https://go.drugbank.com/drugs/DB01239#mechanism-of-action](https://go.drugbank.com/drugs/DB01239#mechanism-of-action)
  - [https://go.drugbank.com/drugs/DB01239#BE0000092](https://go.drugbank.com/drugs/DB01239#BE0000092)
  - [https://www.targetvalidation.org/summary?drug=CHEMBL908](https://www.targetvalidation.org/summary?drug=CHEMBL908)
  - [https://en.wikipedia.org/wiki/Antipsychotic#Mechanism_of_action](https://en.wikipedia.org/wiki/Antipsychotic#Mechanism_of_action)
  - [https://en.wikipedia.org/wiki/Mesolimbic_pathway#Relation_to_neurological_and_psychological_disorders](https://en.wikipedia.org/wiki/Mesolimbic_pathway#Relation_to_neurological_and_psychological_disorders)
  - [https://en.wikipedia.org/wiki/Schizophrenia#Medication](https://en.wikipedia.org/wiki/Schizophrenia#Medication)
